Counting the costs of how drug resistance undermines cancer care
David McKinney and Mo Putera of ARMoR discuss a preliminary economic analysis of how drug-resistant infections erode the value of cancer care, quantifying lost treatment benefits, additional hospital costs and the potential returns from targeted interventions in addressing antimicrobial resistance (AMR).
The progress that is being made in successfully treating cancer with less invasive medicines is being threatened by drug resistant infections to which people with cancer are particularly vulnerable. Photo by Christopher Nicholas at the Sri Lanka Cancer Society.
HIGHLIGHTS
- David McKinney and Mo Putera explain how a report by the Alliance for Reducing Microbial Resistance (ARMoR) estimates the value of cancer treatment lost when drug-resistant infections interrupt care or contribute to premature death.
- The US case study identifies USD105 million in lost treatment benefit and around USD121 million in additional hospital costs each year, caused by drug-resistant infections in patients with cancer related neutropenia.
- ARMoR highlights the potential value of action: in just one patient group, infection prevention and control, antimicrobial stewardship and new antimicrobials could together preserve an estimated USD7.4 billion in health value in the US cancer population by 2050.
- They argue for bringing cancer and AMR policies closer together, supported by better data and greater recognition of the economic value of preventing and treating infections.
Due to the immunosuppressive nature of cancer and treatments such as chemotherapy, radiotherapy, and complex surgeries, people living with cancer are uniquely vulnerable to infections. Approximately 1 in 5 cancer patients are hospitalised due to an infection during their treatment, making effective antimicrobials such as antibiotics and antifungals their primary line of defence.
However, more and more bacteria, viruses, fungi, and other microbes that cause infections are developing resistance to the medicines designed to kill them, and the standard antimicrobial regimens that oncology teams rely on are losing their efficacy. So, while cancer treatments become ever more effective, such progress is at risk if patients must delay, interrupt, or stop treatment due to a drug-resistant infection.
Antimicrobial resistance (AMR) has real human, medical, and financial costs. It causes treatment delays, drives up healthcare costs, and leads to premature mortality, with patients at risk of dying from an untreatable infection even when their cancer is treatable.
A new economic analysis by the Alliance for Reducing Microbial Resistance (ARMoR), developed with input from UICC and experts from its AMR and Cancer care Task Force, estimates the scale of these losses.
“We fund and pay for cancer treatments based on the expected outcome from that treatment,” explains David McKinney, co-founder and director of ARMoR. “If a patient dies or has a delayed treatment, due to a difficult-to-treat drug-resistant infection, we essentially lose the health, economic, and social benefits that the cancer treatment was supposed to bring to them, in addition to the human toll on individuals and their families.”
The analysis also highlights how the financial impact can extend into subsequent cancer care. If an infection disrupts treatment and the cancer progresses or relapses, more intensive and expensive therapies may be required. In fact, research by Menarini, a UICC partner, indicates that the true cost of AMR in cancer care extends far beyond treating the infection itself. The largest share of additional expenditure may come from the impact on cancer care, including disrupted or prolonged treatment, additional procedures and surgery.
Using available data to estimate the cost of AMR
The ARMoR report, Exploring the Economic Impacts of Drug Resistant Infections on Cancer Care, examines three case studies in the United States, Italy and Spain. “We found that each death from a drug-resistant infection represents an estimated USD95,000 to USD184,000 in lost cancer treatment value and USD260,000 to USD1.6 million in lost health value, while each episode adds USD25,000 to USD29,000 in hospital costs, depending on the setting and patient group,” says McKinney
For US cancer patients hospitalised with febrile neutropenia (a fever accompanied by a very low number of white blood cells that fight infections), the report estimates that drug-resistant infections are associated with USD105 million in lost cancer treatment benefit each year, alongside approximately USD121 million in additional hospital costs and USD896 million in lost health value.
“We estimate that the estimated 567 deaths annually represent 5,971 quality-adjusted life years lost,” says McKinney referring to US data. “A QALY is a way of measuring the impact of a health condition on both the length and quality of someone’s life. To put a monetary value on that loss, we use a US threshold of USD150,000 per QALY.”
The report also estimates annual losses of USD26 million in cancer treatment value and USD72 million in health value among Italian patients with blood cancers, such as leukaemia, and certain drug-resistant bloodstream infections. For Spanish patients with any type of cancer and certain drug-resistant bloodstream infections, the corresponding estimates are USD9 million and USD24 million.
Mo Putera, Head of Research at ARMoR, explains that these figures do not represent the full burden of AMR in cancer care. “Ideally, we would follow patients with the same cancer, infection, and resistance profile, tracking their outcomes and costs. But those datasets generally don’t exist, so we built specific case studies using the best available evidence for each country, cancer, and infection type, choosing conservative estimates where possible.”
The geographical limitations are also significant. Most of the analysis focuses on Western countries, and the authors could not produce reliable estimates for paediatric cancer. McKinney agrees, however, that although the available evidence does not allow them to quantify it, the burden is likely to be greater in low- and middle-income countries, where AMR rates are estimated to be higher, and infection prevention and control measures and access to effective antimicrobials and diagnostics more limited.
“Introducing immunocompromising cancer therapies in settings without adequate infection prevention and infection management may actually create additional risks,” says McKinney.
Breaking down siloes for a cost-effective response
For McKinney, one reason the threat of AMR remains under-recognised is that cancer and infection are too often considered separately, both in clinical practice and in health policy. “In some settings, oncologists manage infections without specialist infectious disease input, or must bring in external expertise,” he says. “Inadequate testing and management can add costs and increase the risk of poor outcomes, while deaths in people with cancer that are caused or contributed to by secondary infections may still be recorded as cancer deaths, making the role of infection in cancer care less visible in health data.”
McKinney argues that infection management and addressing antimicrobial resistance should be addressed more explicitly in national cancer control plans, with infectious diseases specialists involved in their development. The ARMoR report identifies cancer organisations, pharmaceutical companies, and policymakers as important audiences for its findings. It also points to the need for better linked data to support decisions about cancer financing and infection management.
“Our analysis examines three complementary areas of intervention: infection, prevention and control (IPC), appropriate use of existing antimicrobials through effective stewardship, which means making sure antimicrobials are used appropriately and only when needed, and the development of new antimicrobials. Its projections for US cancer patients hospitalised with febrile neutropenia estimate that each of these measures could preserve between approximately USD2.5 billion and USD3.1 billion in health value by 2050. Combined, they could preserve an estimated USD7.4 billion.”
Putera stresses how narrow that patient group is. “These projections cover only cancer patients admitted to hospital in the US with febrile neutropenia. Admissions of that kind make up about one in 20 cancer-related hospital stays in the country, and we count only the fraction with a bacterial infection. We leave out infections after surgery, infections treated outside hospital, fungal infections, the knock-on costs when treatment is delayed or the cancer relapses, and every other country. So the USD7.4 billion is the value at stake in one narrow group, and the total across cancer care is likely to be far greater.”
These projections are more provisional than the estimates of the existing burden. Putera explains that the researchers used conservative assumptions about the potential effectiveness of each intervention and applied a layered risk-reduction approach, known as the Swiss cheese model, where no single intervention can address AMR alone. Different measures provide complementary layers of protection across the infection pathway, from preventing infections in the first place to ensuring that effective treatment remains available when infections occur.
“Some measures don’t depend on the development of new medicines, however, and could be introduced relatively quickly,” McKinney emphasises. “These include strengthening IPC, ensuring that appropriate microbiological tests are carried out when infections are suspected, making sure antimicrobials are used appropriately and only when needed, and training oncologists in prescribing them.”
Furthermore, he says that the combined benefits are not simply additive because some infections would be prevented by more than one intervention. “A fuller health-economic evaluation is needed to validate and refine the estimates, but the direction is clear. These interventions cost relatively little next to expensive innovative cancer therapies, so they are likely to be a cost-effective way of protecting that investment.”
ARMoR plans to take the work further through more detailed health-economic analysis, research focused on low- and middle-income countries, and engagement with pharmaceutical companies on how they assess and manage infection and AMR risks within oncology development programmes. It also hopes to develop a shared research agenda with cancer organisations, clinicians and AMR specialists.
Last update
Wednesday 18 November 2026